471 related articles for article (PubMed ID: 36116249)
1. Progress and prospects of Sacubitril/Valsartan: Based on heart failure with preserved ejection fraction.
Jia R; Ji Y; Sun D
Biomed Pharmacother; 2022 Nov; 155():113701. PubMed ID: 36116249
[TBL] [Abstract][Full Text] [Related]
2. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
Hubers SA; Brown NJ
Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
[TBL] [Abstract][Full Text] [Related]
3. Sacubitril/Valsartan Initiation Among Veterans Who Are Renin-Angiotensin-Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction.
Mohanty AF; Levitan EB; King JB; Dodson JA; Vardeny O; Cook J; Herrick JS; He T; Patterson OV; Alba PR; Russo PA; Obi EN; Choi ME; Fang JC; Bress AP
J Am Heart Assoc; 2021 Oct; 10(20):e020474. PubMed ID: 34612065
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD
JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin-Neprilysin Inhibition in Patients With Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure.
Mentz RJ; Ward JH; Hernandez AF; Lepage S; Morrow DA; Sarwat S; Sharma K; Starling RC; Velazquez EJ; Williamson KM; Desai AS; Zieroth S; Solomon SD; Braunwald E;
J Am Coll Cardiol; 2023 Jul; 82(1):1-12. PubMed ID: 37212758
[TBL] [Abstract][Full Text] [Related]
6. Effect of Sacubitril/Valsartan on renal function in patients with chronic kidney disease and heart failure with preserved ejection fraction: A real-world 12-week study.
Jia R; Zhang X; Xu Y; Zheng Z; Jiang L; Zhang X; Sun C; Wu X; Li S; Raj A; Sun D
Eur J Pharmacol; 2022 Aug; 928():175053. PubMed ID: 35709921
[TBL] [Abstract][Full Text] [Related]
7. Beneficial and harmful effects of sacubitril/valsartan in patients with heart failure: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis.
Nielsen EE; Feinberg JB; Bu FL; Hecht Olsen M; Raymond I; Steensgaard-Hansen F; Jakobsen JC
Open Heart; 2020 Nov; 7(2):. PubMed ID: 33257469
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.
Solomon SD; Rizkala AR; Gong J; Wang W; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Shi VC; Lefkowitz MP; McMurray JJV
JACC Heart Fail; 2017 Jul; 5(7):471-482. PubMed ID: 28662936
[TBL] [Abstract][Full Text] [Related]
9. Real-world use patterns of angiotensin receptor-neprilysin inhibitor (sacubitril/valsartan) among patients with heart failure within a large integrated health system.
Kim BJ; Huang CW; Chung J; Neyer JR; Liang B; Yu AS; Kwong EK; Park JS; Hung P; Sim JJ
J Manag Care Spec Pharm; 2022 Oct; 28(10):1173-1179. PubMed ID: 36125061
[No Abstract] [Full Text] [Related]
10. A Review of New Pharmacologic Treatments for Patients With Chronic Heart Failure With Reduced Ejection Fraction.
Nguyen E; Weeda ER; White CM
J Clin Pharmacol; 2016 Aug; 56(8):936-47. PubMed ID: 26626162
[TBL] [Abstract][Full Text] [Related]
11. Effect of Sacubitril/Valsartan vs Valsartan on Left Atrial Volume in Patients With Pre-Heart Failure With Preserved Ejection Fraction: The PARABLE Randomized Clinical Trial.
Ledwidge M; Dodd JD; Ryan F; Sweeney C; McDonald K; Fox R; Shorten E; Zhou S; Watson C; Gallagher J; McVeigh N; Murphy DJ; McDonald K
JAMA Cardiol; 2023 Apr; 8(4):366-375. PubMed ID: 36884247
[TBL] [Abstract][Full Text] [Related]
12. Effect of sacubitril/valsartan and ACEI/ARB on glycaemia and the development of diabetes: a systematic review and meta-analysis of randomised controlled trials.
Wang R; Ye H; Zhao Y; Wei J; Wang Y; Zhang X; Wang L
BMC Med; 2022 Dec; 20(1):487. PubMed ID: 36527023
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and Safety of Sacubitril/Valsartan in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.
Mou Y; Qin L; Wang L; Guo Y; Zhang X; Yu J
Altern Ther Health Med; 2024 Apr; 30(4):190-197. PubMed ID: 37917889
[TBL] [Abstract][Full Text] [Related]
14. Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan.
Yang M; Butt JH; Kondo T; Jering KS; Docherty KF; Jhund PS; de Boer RA; Claggett BL; Desai AS; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Langkilde AM; Martinez FA; Petersson M; Shah SJ; Vaduganathan M; Wilderäng U; Solomon SD; McMurray JJV
Eur J Heart Fail; 2022 Dec; 24(12):2307-2319. PubMed ID: 36342375
[TBL] [Abstract][Full Text] [Related]
15. Evaluating sacubitril/valsartan as a treatment option for heart failure with reduced ejection fraction and preserved ejection fraction.
Raschi E; Diemberger I; Sabatino M; Poluzzi E; De Ponti F; Potena L
Expert Opin Pharmacother; 2022 Feb; 23(3):303-320. PubMed ID: 35050813
[TBL] [Abstract][Full Text] [Related]
16. Sacubitril/Valsartan: A New Dawn has Begun! A Revisited Review.
Abdelnabi M; Saleh Y; Almaghraby A; Girgis H; Gerges F
Curr Cardiol Rev; 2022; 18(3):e310821195982. PubMed ID: 34488614
[TBL] [Abstract][Full Text] [Related]
17. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E
Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956
[TBL] [Abstract][Full Text] [Related]
18. Utilization of sacubitril/valsartan in patients with heart failure with reduced ejection fraction: real-world data from the ARIADNE registry.
Zeymer U; Clark AL; Barrios V; Damy T; Drożdż J; Fonseca C; Lund LH; Kalus S; Ferber PC; Hussain RI; Koch C; Maggioni AP
Eur Heart J Qual Care Clin Outcomes; 2022 Jun; 8(4):469-477. PubMed ID: 33725113
[TBL] [Abstract][Full Text] [Related]
19. Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension.
Codina P; Domingo M; Barceló E; Gastelurrutia P; Casquete D; Vila J; Abdul-Jawad Altisent O; Spitaleri G; Cediel G; Santiago-Vacas E; Zamora E; Ruiz-Cueto M; Santesmases J; de la Espriella R; Pascual-Figal DA; Nuñez J; Lupón J; Bayes-Genis A
ESC Heart Fail; 2022 Aug; 9(4):2170-2180. PubMed ID: 35588235
[TBL] [Abstract][Full Text] [Related]
20. The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond.
Kario K
Curr Cardiol Rep; 2018 Jan; 20(1):5. PubMed ID: 29374807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
